Sunitinib efficacy against advanced renal cell carcinoma.
about
Interventions for skin reactions associated with targeted anticancer treatmentsInterventions for skin reactions associated with targeted anticancer treatmentsRole of immunotherapy for renal cell cancer in 2011Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsHeme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaSunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data.Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerSunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation studyIntraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in KoreaMetabolism considerations for kinase inhibitors in cancer treatmentNovel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysisPRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Future directions in renal cell carcinoma: 2011 and beyondRECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cellsLysosomal sequestration of sunitinib: a novel mechanism of drug resistance.Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysisDiffering von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECISTIdentification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.Experience with sunitinib in the treatment of metastatic renal cell carcinomaMetastatic gastric tumors arising from renal cell carcinoma: Clinical characteristics and outcomes of this uncommon disease.Therapeutic challenges in advanced renal cell carcinomaSunitinib therapy in renal cell carcinoma.Immunotherapy for renal cell cancer in the era of targeted therapy.Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications.Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resectionVEGF and pleiotrophin modulate the immune profile of breast cancer.Protein kinase inhibitors: contributions from structure to clinical compounds.
P2860
Q24187823-99F1E428-6B8C-403A-889A-AF67343AC47AQ24235777-C603D4D3-1078-45B3-B809-7BA2F280CDDDQ26853453-5C17A6F3-F075-4CC5-8E6B-BD505C243087Q27673353-6EAE9A2A-B4DD-4687-88D7-4521A064157FQ27853203-5881D335-6FF3-445C-BAFF-FAC5F35D82EDQ28247085-E77ED6AE-0874-430E-9AEA-F6833DAD2864Q30994063-4CD1AA49-AB92-4DD3-96CB-1AF883B19D13Q33383270-4BBE4C12-2265-4FFD-9065-3620A5D516FBQ33397590-2E27F692-8E0F-4A25-8F82-1647EC0A0914Q33409913-B599B30D-040B-4B51-86B0-1458A22ACB6DQ33437427-EF8CD92B-3E12-4BE5-82A1-307FE8ACD6F3Q33577856-3654DD29-C868-424B-91A3-3C32EAACC05AQ33652589-E24D473E-205D-404C-A518-D0D8B448A417Q33843677-2E3BEC48-0C71-445E-BE46-78D213373BACQ33916002-BB3ED82B-81A8-44C5-9A2E-716DD7E79180Q33931392-175588BF-3FF6-4FFA-9CAE-A9213C6F908DQ34134390-2AC449DD-4C1C-4AEC-8370-1520ED884D4BQ34193096-74E6BE4E-42A7-4906-B4FF-EDA59CD69D0AQ34226634-CE932C17-E113-4E9F-8434-F0EA56FA8BDDQ34497997-BAE0E8F0-AB9C-404A-AB51-FE32CC0EC879Q34515993-65AD7003-E1CE-40AB-9CE5-DD1613296EDDQ34616440-D5C042D7-1CD1-46AB-AD71-55A2E7EF0FA7Q35152107-0DA106EC-D2ED-4115-B3E7-8BB877298866Q35156636-24ADB1E9-56ED-4CE4-A6AB-F648360B3DAAQ35678417-46ECB1DB-EDD5-4921-B056-A31799553C3DQ35703000-5F0F7AA5-52A9-49FD-9E10-75826782C552Q35758408-95A48330-5A1F-456C-ABDF-09BB1DA2A9CDQ35990536-462D7268-9528-4016-AE09-9936CDE31B3CQ36015295-707478A0-7336-4750-9C60-ABD8A77284BCQ36088193-8627E78D-9A6F-4200-81B6-155A0FE3A914Q36172732-0BB809E1-A02E-4A80-BD45-F60E5F07BF67Q36231729-20F66C47-D31B-4FB7-B5CA-E5D7FF7CFC8CQ36424062-934BE00A-D950-42A0-8C51-BFF9A5D3D22EQ36573665-BB106867-942B-4042-BD28-CC337C92EC67Q37088460-2D18AB55-C9FD-4948-B81D-98952CAA042BQ37183451-99A1D8BA-BFBE-48E4-A516-D78D816A80B0Q37236302-5C072B0D-192F-4565-A621-F7BAD03614B6Q37265186-194CF978-45AD-4CC0-A41A-75D161AD6ABEQ37328378-7888EEFB-EC60-4529-88C6-1683C130C70CQ37417742-26D9FC67-AB29-42BD-B978-444FA33C58A3
P2860
Sunitinib efficacy against advanced renal cell carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sunitinib efficacy against advanced renal cell carcinoma.
@en
type
label
Sunitinib efficacy against advanced renal cell carcinoma.
@en
prefLabel
Sunitinib efficacy against advanced renal cell carcinoma.
@en
P2093
P1476
Sunitinib efficacy against advanced renal cell carcinoma.
@en
P2093
Brendan D Curti
Bruce G Redman
Daniel J George
Gary R Hudes
Jonathan Rosenberg
Kim A Margolin
M Dror Michaelson
Ronald M Bukowski
P304
P356
10.1016/J.JURO.2007.07.030
P407
P577
2007-09-17T00:00:00Z